Dr. Eichenbaum Presents Data on Wet Macular Degeneration at the American Society of Retina Specialists
Sun, Aug 14, 2016
Dr. Eichenbaum presented work showing the safety and efficacy of ranibizumab (Lucentis) in a certain type of wet age-related macular degeneration (AMD) lesion.   Read more...
David Eichenbaum, MD Wins Best Scientific Poster at the American Academy of Ophthalmology Annual Meeting 2015
Thu, Dec 24, 2015
The Academy selects some of the most significant scientific work presented at the Annual Meeting for recognition each year, and Dr. Eichenbaum's presentation merited the award in 2015.   Read more...
Steven Cohen, MD received Achievement Award at annual meeting in Las Vegas, November 2015
Wed, Dec 2, 2015
Steven Cohen, MD received Achievement Award at annual meeting in Las Vegas, November 2015
Having contributed to the scientific program regularly over the past 20 years, Dr. Cohen was honored this year with an Achievement award.   Read more...
David A. Eichenbaum, MD receives Michael R. Redmond, MD, Outstanding Young Ophthalmologist Award
Thu, July 9, 2015
David A. Eichenbaum, MD receives Michael R. Redmond, MD, Outstanding Young Ophthalmologist Award
JACKSONVILLE, Fla. — The Florida Society of Ophthalmology (FSO),the preeminent professional association for medical and osteopathic physicians who specialize in vision care, is pleased to announce that David A. Eichenbaum, MD received the Michael R. Redmond, MD Outstanding Young Ophthalmologist Award at its Annual Meeting, Masters in Ophthalmology 2015, June 26-28 in Palm Beach, Fla.   Read more...
Treating Retinal Blindness - Gene Therapy, Stem Cell Therapy, Retinal Chips - April 2014 - Charlie Rose Show
Tue, Jan 6, 2015
Treating Retinal Blindness - Gene Therapy, Stem Cell Therapy, Retinal Chips - April 2014 - Charlie Rose Show
This is a one hour show about research on treatments for blindness. It features an excellent panel of experts: Eric Kandel of Columbia University, Sanford Greenberg, Chairman of the Board of Governors of Johns Hopkins Wilmer Eye Institute ; Jean Bennett; Steven Schwartz of the Jules Stein Eye Institute; Eberhart Zrenner & Carla Shatz of Stanford University.   Read more...
Lucentis Reduces Diabetic Retinopathy
Mon, Dec 1, 2014
Lucentis Reduces Diabetic Retinopathy
Diabetic retinopathy has been a major cause of vision loss in working-age adults. To date, there have been effective treatments to reduce progression of diabetic retinopathy, but there has so far been no way to reverse the disease process. In the recent pivotal RISE and RIDE trials, monthly Lucentis was shown to actually improve the stage of diabetic retinopathy over 3 years. It is the first FDA-approved treatment to publish this finding.   Read more...
Eylea approved for daibetic macular edema
Mon, Dec 1, 2014
Eylea approved for daibetic macular edema
Diabetic macular edema is a leading cause of vision loss among working-age adults in the U.S., and we are pleased to be able to offer a new treatment option to these patients. Treatment with EYLEA can help improve and maintain vision with every 8 week dosing after 5 initial monthly doses. EYLEA is the first VEGF inhibitor approved for dosing on a less than monthly basis for the treatment of DME.   Read more...
Pages 1